Tb Hypersensitivity Pleural Effusion

---

DISCLAIMER: This reference provides evidence-based medical information for educational and clinical guidance purposes only. It is not a substitute for professional medical judgment, diagnosis, or treatment. Decisions regarding patient care must be made by qualified healthcare professionals based on the patient's individual condition and current clinical guidelines.

---

Overview

Definition

Tuberculous (Tb) pleuritis is an exudative pleural effusion caused by a hypersensitivity reaction to Mycobacterium tuberculosis antigens released into the pleural space, typically following the rupture of a subpleural caseous focus. It is often the first manifestation of M. tuberculosis infection or occurs secondary to primary pulmonary infection, representing a containment phase rather than widespread disease.

Epidemiology

• Most Common Cause: Tb pleuritis is the most common cause of exudative pleural effusions in regions where tuberculosis is endemic, and remains a significant cause in areas with low endemicity, especially among immigrants, immunocompromised individuals (HIV/AIDS), and the elderly.
• Age: Predominantly affects young adults (ages 20–40), although the age range is shifting upward in developed countries due to reactivation in older cohorts.
• Association: Occurs in approximately 5–15% of patients with primary pulmonary tuberculosis.

Classification

Tuberculous pleuritis is primarily classified by the stage of infection: * Primary Tb Pleuritis: Occurs shortly after the initial M. tuberculosis infection (typically within 6 months), often presenting as an isolated effusion without overt radiographic pulmonary disease. * Post-Primary (Reactivation) Tb Pleuritis: Occurs years after initial infection, often alongside active pulmonary or extrapulmonary disease, though an isolated effusion is still common.

Pathophysiology

Mechanism

Tb pleuritis is characterized by a delayed-type hypersensitivity (Type IV) reaction: 1. Antigen Entry: A small, subpleural focus of M. tuberculosis infection ruptures into the pleural space, releasing mycobacterial antigens and potentially a small number of bacilli. 2. Immune Response: Macrophages and T-lymphocytes (specifically CD4+ T-helper cells) recognize the antigens. This triggers a robust local immune response. 3. Cytokine Cascade: Activated T-cells release pro-inflammatory cytokines, including Interferon-gamma (IFN-$\gamma$), Interleukin-2 (IL-2), and Tumor Necrosis Factor-alpha (TNF-$\alpha$). 4. Pleural Permeability: These cytokines increase vascular permeability in the pleural capillaries, leading to the rapid accumulation of protein-rich fluid (exudate) and migration of inflammatory cells (predominantly lymphocytes) into the pleural space. 5. Granuloma Formation: If left untreated, the visceral pleura reacts with thickened, nodular, and often caseating granulomas, which can lead to pleural thickening and fibrosis.

Risk Factors

• Endemic exposure to M. tuberculosis.
• Previous history of latent TB infection (LTBI).
• Immunosuppression: HIV infection (especially CD4 counts >200 cells/µL, though it can occur at any stage), solid organ transplantation, chronic corticosteroid use, anti-TNF-$\alpha$ therapy.
• Diabetes mellitus.
• Chronic kidney disease (CKD).
• Malnutrition.
• Alcoholism, IV drug use.
• Advanced age.

Protective Factors

• Successful completion of treatment for latent or active TB.
• Effective innate and adaptive cellular immunity (high CD4+ count in HIV-negative individuals).

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Pleuritic Chest Pain: Sharp, local pain exacerbated by deep inspiration or coughing (common in young, otherwise healthy patients).
  • Fever: Usually mild to moderate (low-grade, intermittent).
  • Dyspnea: Proportional to the size of the effusion.
  • Cough: Non-productive or mild, often secondary to pleural irritation.
  • Constitutional Symptoms: Anorexia, malaise, weight loss, night sweats (less prominent than in pulmonary TB).
• Early Signs: Unilateral, rapidly developing pleuritic chest pain and fever.
• Advanced Signs: If diagnosis is delayed: significant weight loss, clubbing (rare, but can occur with long-standing disease), signs of widespread systemic TB, or pleural thickening/fibrosis.
• Atypical Presentations:
  • Effusion accompanied by high fever/sepsis-like picture (especially in immunocompromised).
  • Asymptomatic effusion (found incidentally on X-ray, more common in the elderly or immunocompromised).
  • Bilateral effusions (rare, occurs in <5% of cases).

Physical Examination

• Inspection: Decreased chest expansion on the affected side.
• Palpation:
  • Tracheal deviation away from the affected side (if effusion is large).
  • Diminished or absent tactile fremitus over the effusion.
• Percussion: Dullness or flatness over the area of the effusion.
• Auscultation:
  • Diminished or absent breath sounds over the effusion.
  • Pleural friction rub (rare, may be heard early before significant fluid accumulation).
  • Egophony and E to A alteration at the superior fluid margin.

Diagnostic Approach

The diagnosis relies on demonstrating typical exudative fluid characteristics, identifying an overwhelming predominance of lymphocytes, and confirming the presence of M. tuberculosis antigen or organisms, often requiring invasive procedures.

History Taking

• Key Questions:
  • Recent exposure to individuals with active TB (household, workplace).
  • Countries of origin or travel to high-prevalence areas.
  • History of Bacille Calmette-Guérin (BCG) vaccination.
  • Systemic immunosuppression (HIV status, medication history: biologics, steroids).
  • B-symptoms (fever, night sweats, weight loss).
• Red Flags:
  • Rapid accumulation of effusion with hemodynamic instability (consider concurrent acute bacterial empyema or malignancy, though rare in Tb).
  • Concurrent symptoms suggestive of miliary TB or CNS involvement.
  • History of treatment for latent TB infection (LTBI) without successful completion.

Laboratory Tests

First-Line

1. Thoracentesis and Pleural Fluid Analysis: Essential for diagnosis.

   • Appearance: Serosanguinous or straw-colored (clear yellow).
   • Classification: Exudative (meets Light's criteria).
     • Pleural Fluid Protein/Serum Protein ratio >0.5
     • Pleural Fluid LDH/Serum LDH ratio >0.6
     • Pleural Fluid LDH >2/3 the upper limit of normal for serum LDH.
   • Cell Count: Typically 1,000–6,000 cells/µL.
   • Differential: High predominance of lymphocytes (>50% to >90%). Early-stage effusions (within the first week) may show a transient neutrophil predominance.
   • Glucose: Usually low (<60 mg/dL), sometimes very low (<40 mg/dL), but higher than in empyema.
   • pH: Low (7.2–7.3), but usually >7.0.

2. Adenosine Deaminase (ADA): The most useful biochemical screening test for TB pleuritis.

   • Cut-off Value: ADA >40 U/L (or >50 U/L in some centers) strongly suggests TB.
   • Sensitivity/Specificity: High sensitivity (90–100%) and specificity (85–95%) in non-endemic areas. Lower cut-offs might be used cautiously in immunocompromised patients. Note: Elevated ADA can also occur in empyema, rheumatoid arthritis, lymphoma.

3. Interferon-Gamma (IFN-$\gamma$): Highly specific and sensitive biomarker.

   • Cut-off Value: Varies, generally >140 pg/mL is highly suggestive. Often used to confirm high ADA levels.

Confirmatory

1. Pleural Fluid Culture:

   • Acid-Fast Bacilli (AFB) Smear: Low yield (usually <10–20%).
   • Mycobacterial Culture (liquid media preferred): Standard for confirmation, but sensitivity is only 30–50% due to the paucibacillary nature of the effusion. Results take 2–6 weeks.

2. Pleural Biopsy (Gold Standard): Necessary when fluid culture is negative, especially if ADA/IFN-$\gamma$ is equivocal.

   • Technique: Blind (Cope or Abrams needles) or Thoracoscopic.
   • Histopathology: Demonstrates caseating granulomas in 60–80% of cases.
   • Biopsy Culture: Culture of the pleural tissue increases the diagnostic yield to 60–80%, and up to 90% when combined with fluid culture.

3. Molecular Diagnostics (NAAT):

   • GeneXpert MTB/RIF: Can be performed rapidly on pleural tissue or fluid. Highly specific (>98%) but sensitivity in paucibacillary fluid is moderate (40–60%). Better sensitivity when performed on pleural biopsy tissue.

Monitoring

• Complete Blood Count (CBC), Liver function tests (LFTs), and Kidney function tests (RFTs) for monitoring therapy toxicity (Hepatotoxicity is common).

Imaging

Recommended

1. Chest Radiograph (CXR):
   • Findings: Unilateral, homogeneous opacification obliterating the costophrenic angle. Usually small-to-moderate effusion (occupying less than half of the hemithorax).
   • Parenchymal Disease: Often absent (50–70% of cases). When present, usually manifests as minimal infiltrates above the effusion or apical scarring.
2. Thoracic Ultrasound:
   • Purpose: Delineates fluid localization, estimates volume, identifies septations (rare in simple Tb effusion), and guides thoracentesis/biopsy. Tb effusions are usually simple (anechoic) early on.

Advanced

1. Computed Tomography (CT) Scan of the Chest:
   • Purpose: Necessary if diagnosis is uncertain, to rule out underlying malignancy, or to quantify degree of pleural thickening (fibrothorax).
   • Findings: Loculated effusion, diffuse (circumferential) pleural enhancement after contrast, and sometimes mediastinal lymphadenopathy.

Management

The cornerstone of treatment for Tb pleuritis is the standard anti-tuberculosis multidrug regimen. Therapeutic drainage is usually not required unless symptoms persist or complications arise (e.g., tension hydrothorax).

Acute Management

Immediate

• Diagnostic Thoracentesis: Perform immediately for fluid analysis to confirm the exudative nature and test for ADA/cells.
• Symptom Relief: NSAIDs for pleuritic chest pain.

Stabilization

• Initiate Anti-tubercular Therapy (ATT): Do not wait for culture confirmation if clinical presentation and pleural fluid analysis (high ADA, lymphocytosis) are highly suggestive.

Emergency

• Therapeutic Drainage: Indicated only for significant symptomatic relief (severe dyspnea due to large effusion) or large effusions causing hemodynamic compromise (rare). Drain 1.0–1.5 L slowly.

Chronic Management

Pharmacological

Standard Four-Drug Regimen (IDSA/ATS/CDC/WHO Guidelines): Tb pleuritis is treated as pulmonary tuberculosis, even if the chest X-ray appears clear, due to the high risk of progression to active systemic disease.

1. Intensive Phase (Initial 2 months):
   • Isoniazid (INH): 5 mg/kg daily (max 300 mg)
   • Rifampin (RIF): 10 mg/kg daily (max 600 mg)
   • Pyrazinamide (PZA): 15–30 mg/kg daily (max 2000 mg)
   • Ethambutol (EMB): 15–25 mg/kg daily (max 1600 mg)
2. Continuation Phase (Subsequent 4 months):
   • Isoniazid and Rifampin daily.

Total Treatment Duration: 6 months.

Adjunctive Corticosteroids (Controversial but recommended in selected cases): * Rationale: To reduce pleural inflammation, fluid re-accumulation, and subsequent pleural thickening/fibrosis. * Dosage: Prednisolone 0.5–1.0 mg/kg daily for 2–4 weeks, followed by a gradual taper over several weeks (total course usually 6–8 weeks). * Recommendation: May be considered for patients with large effusions, severe toxicity, or recurrent fever, provided the patient is HIV-negative and multi-drug resistant TB (MDR-TB) has been excluded. Not routinely recommended, but evidence supports faster resolution of fever and effusion.

Non-pharmacological

• Nutritional Support: Address weight loss and malnutrition, common comorbidities.

Monitoring

• Monthly evaluation for clinical improvement (fever resolution, effusion size reduction).
• Monthly monitoring of LFTs/RFTs to detect drug-induced toxicity (especially PZA and INH).

Treatment Algorithms

First-Line

1. High Suspicion (based on ADA/IFN-$\gamma$/Lymphocytosis): Initiate 6-month ATT immediately.
2. Small Effusion, Mild Symptoms: 6-month ATT + symptomatic management (NSAIDs).
3. Large Effusion, Severe Dyspnea: Therapeutic thoracentesis (if necessary) + initiate 6-month ATT.

Second-Line

• MDR-TB Suspicion (history of prior treatment, contact with MDR-TB, highly endemic area): Testing for drug susceptibility is mandatory. Treatment involves individualized regimens including agents like fluoroquinolones, injectables (amikacin, capreomycin), and/or newer agents (bedaquiline, linezolid).

Refractory Cases

• Persistent Symptoms/Non-resolving Effusion (>12 weeks): Re-evaluate the diagnosis (consider malignancy, complicated parapneumonic effusion, or empyema necessitans).
• Pleural Thickening/Trapped Lung: If significant pleural peel develops leading to restrictive lung disease, surgical decortication may be required, typically 6 months or more after initiating ATT.

Complications

Common

• Pleural Thickening (Fibrothorax): The most frequent complication (occurs in up to 50% of patients), resulting from organized inflammatory exudate.
• Delayed Resolution: Effusion and chest pain may take weeks to months to completely resolve.

Serious

• Tuberculosis Empyema (TPE): Formation of thick, purulent pleural fluid requiring tube thoracostomy and potentially decortication. Often characterized by high neutrophils, very low glucose (<40 mg/dL), and positive AFB smear/culture.
• Active Pulmonary TB: Progression to active pulmonary disease, typically involving the lung adjacent to the effusion.

Long-term

• Restrictive Lung Disease: Due to significant fibrothorax and trapped lung, leading to chronic dyspnea.

Prognosis

Factors

• Favorable Factors: Early diagnosis, prompt initiation of standard ATT, HIV-negative status.
• Unfavorable Factors: Delayed treatment, immunosuppression (especially low CD4 count), development of MDR-TB, presence of active pulmonary disease.

Survival

• With appropriate 6-month ATT, mortality is low (<5%).
• The risk of developing active pulmonary or extrapulmonary TB later in life is significantly reduced but not eliminated if treatment is completed.

Quality of Life

• Most patients recover well; however, a significant minority (15–20%) experience chronic dyspnea and functional limitation due to restrictive lung disease following pleural thickening.

Prevention

Primary

• TB Infection Control: Minimize exposure to active pulmonary TB patients.
• BCG Vaccination: Provides protection against severe forms of TB (miliary TB, meningitis) in endemic settings, but variable protection against pulmonary disease and pleural TB.

Secondary

• Treatment of LTBI: Identifying and treating latent TB infection in high-risk individuals (e.g., close contacts, immunocompromised) prevents progression to active disease, including pleuritis. Standard INH for 9 months or RIF for 4 months.

Tertiary

• Adherence to ATT: Ensuring completion of the full 6-month regimen to prevent recurrence and further complications (e.g., trapped lung).

Special Populations

Pediatric

• Tb pleuritis is less common in children, usually occurring during primary infection.
• Diagnosis can be difficult as symptoms may be less specific.
• Diagnosis relies heavily on ADA and TST/IGRA.
• Treatment regimen is identical, but dosages are strictly weight-based.

Geriatric

• May present atypically (e.g., asymptomatic effusion, less severe fever) and often have coexisting conditions (CKD, malignancy).
• Higher risk of drug toxicity (especially hepatotoxicity from INH and PZA). Careful renal dosing of EMB and close LFT monitoring are required.

Pregnancy

• Tb pleuritis requires immediate treatment. ATT is generally safe during pregnancy.
• Regimen: Standard 6-month regimen (INH, RIF, EMB) is safe. PZA is generally avoided unless the risk of resistant TB is high, although data suggest it is likely safe. Pyridoxine (Vitamin B6) supplementation (25–50 mg daily) is essential with INH.

Comorbidities (HIV/AIDS)

• Presentation: Effusions may be less lymphocytic and more often non-specfic or neutrophilic. Lower ADA levels may be observed if CD4 <100 cells/µL.
• Treatment: Standard 6-month ATT is required.
• Drug Interactions: Rifampin interacts significantly with many antiretroviral therapies—careful coordination with an HIV specialist is crucial. Rifabutin may be used instead of Rifampin in certain complex regimens.
• Immune Reconstitution Inflammatory Syndrome (IRIS): Patients starting ART soon after ATT may develop worsening effusions or fever due to IRIS.

Clinical Pearls

Diagnostic

• The Power of ADA: If the pleural fluid is a lymphocytic exudate and the ADA level is high (>40 U/L), the diagnosis is TB pleuritis until proven otherwise, especially in endemic areas. Treat empirically while waiting for culture/biopsy.
• Neutrophilic TB: A transient neutrophil predominance (>50%) can occur in the first week of effusion formation. Do not rule out TB solely based on neutrophils if other factors (high ADA, clinical context) support it.
• Biopsy is Key: If the fluid ADA is equivocal or the culture is persistently negative and clinical suspicion remains high, thoracoscopy and pleural biopsy offers the highest definitive yield.

Treatment

• Consistency: The 6-month drug regimen must be completed, even if the effusion resolves quickly (usually within 4–6 weeks).
• Steroid Caution: Use corticosteroids judiciously; only for large, symptomatic effusions in non-HIV patients. They accelerate fluid clearance but do not impact the core treatment length or long-term risk of pleural thickening significantly.

Pitfalls

• Misinterpreting Pleural Fluid: Failing to consider TB in a lymphocytic exudate, especially if the patient is elderly or if the effusion is unilateral and persistent.
• Stopping Treatment Early: Premature cessation of ATT dramatically increases the risk of recurrence and drug resistance.
• Underestimating MDR-TB Risk: If the patient has a history of prior TB treatment, do not use the standard regimen without obtaining drug susceptibility testing.

Recent Updates

Guidelines

• WHO Guidelines (2020/2022): Strongly reaffirm the 6-month standard regimen. Emphasize the expanded use of molecular diagnostics (GeneXpert) on extrapulmonary samples, including pleural tissue/fluid, to guide initial therapy and resistance profiling quickly.
• ATS/CDC (2017): Simplified recommendations for LTBI treatment now offer shorter, rifamycin-based regimens (e.g., RIF 4 months), which may indirectly reduce the future incidence of Tb pleuritis.

Evidence

• Biomarker Utility: Continued research confirms that the combination of high ADA and high IFN-$\gamma$ in pleural fluid offers near-diagnostic certainty for TB pleuritis (approaching 99% specificity), often negating the requirement for invasive biopsy in high-prevalence settings.
• Steroid Debate: Ongoing meta-analyses provide moderate evidence that corticosteroids reduce the time to resolution of fever and effusion, but robust evidence for preventing long-term fibrothorax remains weak. They are typically reserved for patients with larger effusions to improve early morbidity.

Controversies

• Therapeutic Thoracentesis: The role of large-volume drainage remains unclear. While it relieves dyspnea, no clear evidence supports that it prevents subsequent pleural thickening compared to simple diagnostic aspiration followed by ATT.
• Optimal Biopsy Method: Whether large-bore needle biopsy (Cope/Abrams) offers similar diagnostic yield to VATS-guided biopsy in an era of advanced molecular testing. Thoracoscopy (VATS) provides better access to multiple sites and is highly effective, but more invasive.

Key References

Guidelines

• World Health Organization (WHO): Guidelines for the programmatic management of drug-susceptible tuberculosis (2020).
• American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA)/Centers for Disease Control and Prevention (CDC): Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2017).

Studies

• Light, R. W. Pleural Diseases. 6th edition (2013). (Definitive text on fluid analysis).
• Consensus Statement: Diagnostic standards and classification of tuberculosis in adults and children. (Landmark paper defining diagnostic criteria).

Reviews

• J. O. S. Lee, G. A. Lee, E. Y. Cho, S. J. Lee. Tuberculous Pleural Effusion: A Comprehensive Review on Pathogenesis to Treatment. J Clin Med (2020).